Foamix (FOMX) Reports First Patient Enrollment in Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% & Adapalene 0.3% Combination Foam
Tweet Send to a Friend
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), today announced that the first patient has been enrolled in its Phase 2 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
